09:17 AM EDT, 07/02/2024 (MT Newswires) -- Emergent Biosolutions ( EBS ) said Tuesday it has secured contract modifications totaling more than $250 million from the US Department of Health and Human Services' Administration for Strategic Preparedness and Response.

The contracts include $30 million to supply Cyfendus this year; $99.9 million for ACAM2000; and two new contract options worth $122.9 million to supply VIGIV and BAT to the Strategic National Stockpile, the company said.

Shares of Emergent Biosolutions ( EBS ) were up almost 2% in Tuesday premarket activity.

Price: 7.20, Change: +0.14, Percent Change: +1.98